INTRODUCTION
cancer, nausea and vomiting, CINV
CANCER
Concurrent use of multiple antiemetic agents targeting different molecular pathways involved in eliciting chemotherapy‐induced nausea and vomiting (CINV) has transformed supportive care for cancer patients undergoing emetogenic chemotherapy.While the guidelines generally make antiemetic recommendations based on the emetogenicity of the chemotherapy, it is well‐established that several patient‐related factors also affect a patient's risk of CINV.Because cisplatin is well‐established as the most emetogenic chemotherapeutic, it has served as the standard emetic stimulus for the majority of clinical trials assessing the efficacy of antiemetic agents.NKThe current head‐to‐head comparative study (NCT03831633) was conducted to evaluate NEPA versus an aprepitant standard‐of‐care (SoC) regimen in real‐world clinical practice in patients receiving either AC or MEC. The primary results of the study assessing efficacy during the traditional 0–120 h time interval were previously publishedThis study uniquely assessed CINV prevention up to 144 h post‐chemotherapy. Herein we describe the comparative efficacy results of NEPA versus the aprepitant regimen beyond the traditional delayed phase in the patients receiving MEC in this study. Additionally, we explore the outcomes during the same time intervals in the subset of MEC patients who presented with patient‐related emetic risk factors.